Cited by 29Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchProtease and Inhibitor Mechanisms

Progress Toward Identification of Protease Activity Involved in Proteolysis of Apolipoprotein E in Human Brain

Marques, Marcos A., Owens, Phillip A., Crutcher, Keith A.·2004·Journal of Molecular Neuroscience

Abstract

Apolipoprotein E (apoE) genotype is the single most important genetic risk factor for the most common (sporadic) form of Alzheimer's disease (AD). Increasing evidence supports the hypothesis that the presence of the E4 isoform of this cholesterol-binding protein contributes directly to disease risk, age of onset, and severity of the neuropathology. For example, studies in transgenic mice demonstrate that apoE is necessary for the formation of plaques with neuritic pathology. The precise mechanism by which apoE contributes to the disease remains unknown. However, several lines of investigation from a number of laboratories now point to a role for proteolytic fragments of apoE in the formation of both plaques and tangles, the two pathological hallmarks of the disease. In particular, the C-terminal portion of apoE has been implicated in binding to amyloid and is localized to plaques. The N-terminal domain, on the other hand, is neurotoxic in culture and has been localized to, and implicated in the formation of, neurofibrillary tangles. These results suggest that inhibition of apoE proteolysis is a potential therapeutic strategy for AD. Using human brain homogenates, we have determined that proteolysis of apoE is greatest at acidic pH and can be inhibited by compounds targeting aspartic proteases. The feasibility of screening candidate inhibitors is supported by both ELISA and immunoblotting methods. Future studies will use a combination of in vitro and in vivo assays to test the…

Integrity signals

Registry

Crossref · 10.1385/jmn:24:1:073

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Marques, M. A., Owens, P. A., & Crutcher, K. A.
Affiliations
University of Cincinnati (US)
Corresponding author
Crutcher, Keith A.
Venue
Journal of Molecular Neuroscience
Published
2004
Volume
24
Issue
1
Pages
073-080
ISSN
0895-8696 (ISSN-L)
OpenAlex
W2021255192
Cited by
29
References
74
Citations by year
2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 2
FWCI
0.61
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Molecular Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords
apolipoprotein E, Alzheimer's disease, aspartic protease, protease inhibitors, APOE ε4, amyloid plaques, neurofibrillary tangles, human brain, inhibitor screening, transgenic mouse model
MeSH terms
Alzheimer Disease, Animals, Apolipoproteins E, Brain, Drug Evaluation, Preclinical, Enzyme Inhibitors, Humans, Peptide Fragments, Peptide Hydrolases, Neurofibrillary Tangles, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review